Metaxalone

CAS 1665-48-1 11 current records 9 historicalSmall Molecule

Who holds supplier records for Metaxalone? 11 organisations hold a current record for Metaxalone: an active US FDA Type II Drug Master File. A further 9 organisations have only historical (inactive) DMF filings. Recorded organisation countries for current records: India (7), Italy (1), United States (1), Taiwan (1) and 1 other country (1).

Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records

Cite as: PharmaTek, “Metaxalone: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/metaxalone

Reading the evidence

  • 11 current records

    Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.

  • Most recorded organisations are in India

    7 of the 11 current records with a recorded country list India. Organisation country is not necessarily the manufacturing site.

  • 5 with a company-level GMP certificate on record

    These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.

  • US product patents listed

    The latest patent listed in the FDA Orange Book for an approved product containing Metaxalone expires 14 May 2043. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.

Current records (11)

Organisations holding an active US FDA Type II Drug Master File or a CEP for Metaxalone. Country is the organisation's recorded country, not necessarily the manufacturing site.

Need Metaxalone sourced and checked?

The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.

Request sourcing help

Historical records (9)

Organisations whose Type II DMFs for Metaxalone are no longer active. These show a past filing, not current supply.

Show all 9 historical records
  • India · Inactive DMF 28569 · filed Nov 2014
  • Germany · Inactive DMF 23877 · filed May 2010
  • CHUNGHWA CHEMICAL SYNTHESIS AND BIOTECH CO LTD
    Inactive DMF 23434 · filed Jan 2010
  • India · Inactive DMF 16449 · filed Mar 2003
  • Inactive DMF 15609 · filed Aug 2001
  • PHARMACEUTICAL FINE CHEMICALS PFC BAHAMAS LTD
    Inactive DMF 15365 · filed Apr 2001
  • India · Inactive DMF 14395 · filed Sept 1999
  • BOEHRINGER INGELHEIM CHEMICALS INC
    Inactive DMF 6530 · filed Jul 1986
  • ROCHE DIAGNOSTICS GMBH
    Inactive DMF 5435 · filed Jun 1984

US product patents and exclusivity

The FDA Orange Book lists patents and exclusivities for specific approved products (8 listed products contain Metaxalone). The latest listed patent expires 14 May 2043. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.

Overview

Metaxalone is a muscle relaxant prescribed to relieve discomfort associated with acute skeletal muscle conditions. It is typically used as an adjunct to rest, physical therapy, and other measures to relieve discomfort.

Chemical identity

IUPAC name
5-[(3,5-dimethylphenoxy)methyl]-1,3-oxazolidin-2-one
Canonical SMILES
CC1=CC(=CC(=C1)OCC2CNC(=O)O2)C
InChIKey
IMWZZHHPURKASS-UHFFFAOYSA-N
Synonyms
Skelaxin API, ahr-438, flexura, nsc-170959, skelaxin, zorane

Pharmacologic class

As the US FDA states it for this active substance on product listings.

Established pharmacologic class
Muscle Relaxant
Physiologic effect
Centrally-mediated Muscle Relaxation

Therapeutic areas

Musculoskeletal DisordersMuscle Spasms

Record history

No change to the current records between 13 Nov 2026 and 16 Nov 2026.

Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week

What these records establish

  • An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
  • A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
  • Historical records show a past filing, not current supply.
  • Company GMP certificates are matched to the organisation, not to the site making this substance.
  • A substance missing from these registers is not evidence that no supplier exists.

Frequently asked questions

Which organisations hold current supplier records for Metaxalone?

11 organisations hold an active US FDA Type II Drug Master File or a CEP for Metaxalone: ANGELINI ACRAF SPA (Italy), COHANCE LIFESCIENCES LTD (India), Hetero Drugs Limited (India), INNOVARE LABS PRIVATE LTD (India), LEE PHARMA LTD (India), Piramal Pharma Limited (India), RAKS PHARMA PVT LTD (India) and RISING PHARMA HOLDINGS INC (United States), and 3 more listed on this page. A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.

Which Metaxalone Drug Master Files are active?

ANGELINI ACRAF SPA (DMF 15100), COHANCE LIFESCIENCES LTD (DMF 21251), Hetero Drugs Limited (DMF 28062), INNOVARE LABS PRIVATE LTD (DMF 36167), LEE PHARMA LTD (DMF 37079), Piramal Pharma Limited (DMF 27105), RAKS PHARMA PVT LTD (DMF 23980) and RISING PHARMA HOLDINGS INC (DMF 15087) and 3 more. The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.

What do the historical Metaxalone records mean?

9 organisations have only inactive Type II DMFs for Metaxalone. An inactive DMF records that a filing once existed; it does not show that the organisation supplies the substance today.

Does the FDA Orange Book list patents for products containing Metaxalone?

Yes. The latest patent listed for an approved US product containing Metaxalone expires 14 May 2043, across 8 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.

How do I qualify a Metaxalone supplier?

Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.

For suppliers

Do you supply Metaxalone?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.